B
Bull
Bull · 25%ERAS
$1.99
Scenario price
$18.030
-1.350 (-7.49%)At close
Loading chart…
- High
- 19.590
- Open
- 19.250
- VWAP
- 18.54
- Vol
- 2.89M
- Mkt Cap
- 630.21M
- Low
- 18.000
- Amount
- 53.54M
- EV/EBITDA, TTM
- 0.00
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
AI analysis of Erasca Inc (ERAS)
buyErasca Inc (ERAS) is a good buy right now, trading at $18.03 with a recent RSI of 46.059, indicating it is not overbought. The stock has shown a remarkable year-to-date change of +402.23% and a one-year change of +1026.88%, reflecting strong momentum. Additionally, the recent FDA Fast Track Designation for ERAS-0015 enhances its growth prospects, which is a significant positive catalyst. However, the company reported a substantial net income loss of -$183,440,000 in Q1 2026, which is a key risk to consider.
Valuation Metrics
The current forward P/E ratio for Erasca Inc (ERAS) is 0.00, compared to its 5-year average forward P/E of -4.73.
Alphio AI Price Scenarios for ERAS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ERAS
Events Timeline
News
8.508-24NewsfilterErasca Receives FDA Fast Track Designation for ERAS-0015
- 7.008-14Newsfilter
ARS Pharmaceuticals and Others Under Shareholder Investigation
7.008-10PRnewswireErasca Faces Securities Fraud Allegations
7.008-09PRnewswireErasca Faces Securities Fraud Investigation Amid Class Action Claims
7.008-07PRnewswireErasca Faces Class Action Lawsuit Impacting Stock Price
ERAS FAQ — answered by Alphio AI
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Erasca Inc (ERAS) is a good buy right now, trading at $18.03 with a recent RSI of 46.059, indicating it is not overbought. The stock has shown a remarkable year-to-date change of +402.23% and a one-year change of +1026.88%, reflecting strong momentum. Additionally, the recent FDA Fast Track Designation for ERAS-0015 enhances its growth prospects, which is a significant positive catalyst. However, the company reported a substantial net income loss of -$183,440,000 in Q1 2026, which is a key risk to consider.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.